Distillation of the clinical algorithm improves prognosis by multi-task deep learning in high-risk Neuroblastoma

Male 0303 health sciences Science Gene Expression Profiling Q R 610 Infant Prognosis Risk Assessment Progression-Free Survival 004 3. Good health Gene Expression Regulation, Neoplastic Neuroblastoma 03 medical and health sciences Deep Learning Medicine Humans Female Neoplasm Recurrence, Local Child Algorithms Research Article
DOI: 10.1371/journal.pone.0208924 Publication Date: 2018-12-07T18:25:30Z
ABSTRACT
We introduce the CDRP (Concatenated Diagnostic-Relapse Prognostic) architecture for multi-task deep learning that incorporates a clinical algorithm, e.g., risk stratification schema to improve prognostic profiling. present first application survival prediction in High-Risk (HR) Neuroblastoma from transcriptomics data, task studies MAQC consortium have shown remain hardest among multiple diagnostic and endpoints predictable same dataset. To obtain more accurate needed appropriate treatment strategies, combines component (CDRP-A) synthesizing second (CDRP-N) dedicated one or tasks. The approach leverages advent of semi-supervised structures can flexibly integrate multimodal data internally create processing paths. CDRP-A is an autoencoder trained on gene expression HR/non-HR by Children's Oncology Group, obtaining 64-node representation bottleneck layer. CDRP-N classifier two endpoints, i.e., Event-Free Survival (EFS) Overall (OS). provides HR embedding input shared layer, which branches depart model EFS OS, respectively. control selection bias, evaluated using Data Analysis Protocol (DAP) developed within initiative. was applied Illumina RNA-Seq 498 patients (HR: 176) SEQC study (12,464 Entrez genes) Affymetrix Human Exon Array profiles (17,450 247 primary TARGET NBL cohort. On patients, achieves Matthews Correlation Coefficient (MCC) 0.38 MCC = 0.19 OS external validation, improving over published models. show indeed parametrically associated increasing severity be used better stratify patients' survival.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (50)
CITATIONS (18)